Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for atogepant

  1. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

  2. Headaches in over 12s: diagnosis and management (CG150)

    This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

  3. 170,000 people in England to have further treatment choice for preventing migraine attacks

    In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.